Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureRoss A Soo, Sanjay Popat, Urania Dafni, Adrianus Johannes de Langen, Ernest Nadal, Patricia Iranzo, Maurice Pérol, Giulio Metro, Maria Angeles Sala, Marc Cucurull Salamero, Ferdinando Cerciello, Alfredo Addeo, Manuel Dómine, Youssef Oulkhouir, Nicolas Cloarec, Patrizia Froesch, Heidi Roschitzki-Voser, Barbara Ruepp, Adriana Gasca-Ruchti, Tereza Dellaporta, Solange Peters, Rolf A Stahel, Bartomeu Massuti, Joop de Langen, Anita Hiltbrunner, Rosita Kammler, Sabin Allemann, Manuela Akaltan, Sonja Brülisauer, Nino Giacomelli, Eva Grolimund, Uli Kodjadjiku, Sandra Kulli, Tanja Mombelli, Suganiya Nagarajan, Lionel Nobs, Manuel Papparella, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Thomas Sasse, Susanne Roux, Mirjam Schneider, Sandra Troesch, Patrick Vagenknecht, Michael Wiedemann, Zoi Tsourti, Georgia Dimopoulou, Panagiota Zygoura, Katerina Vervita, Maria Fernández, Laura Benito, Sara Busquet, Eva Pereira, Zuzsanna Maniecka Moser, Priska Rentsch, Pier Luigi Piovano, Joaquín Mosquera Martínez, Adrienne Bettini
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline
10.1016/j.annonc.2025.06.007 · 2025
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies
10.1016/j.ctrv.2018.02.006 · 2018
Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis
10.1158/1535-7163.mct-20-0071 · 2020
Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC
10.1056/nejmoa2403614 · 2024
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
10.1016/j.annonc.2023.10.117 · 2024
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023
Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer
2020
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
10.1158/1078-0432.ccr-08-2904 · 2009
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation
10.1097/jto.0000000000000170 · 2014
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone
2023
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)
2019
Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study
10.1016/j.annonc.2021.08.1797 · 2021
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
10.1038/s41591-023-02554-7 · 2023
Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)
10.1200/jco.23.01891 · 2024
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
10.1016/s2213-2600(19)30084-0 · 2019
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
10.1038/s41591-025-03658-y · 2025
Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722
10.1200/jco.23.01017 · 2024
Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
10.1200/jco.23.02747 · 2024
Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study
2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
10.1016/j.esmoop.2025.105807 · 2025
Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi
10.1016/j.jtho.2025.09.017 · 2025
Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC
10.1056/nejmoa2512071 · 2026
A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-naïve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)
10.1200/jco.24.00533 · 2025
10.1016/s1470-2045(22)00382-5
10.1016/s1470-2045(22)00382-5 · 2022
Preventing infusion-related reactions with intravenous amivantamab—results from SKIPPirr, a phase 2 study: a brief report
10.1016/j.jtho.2025.01.018 · 2025
Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial
10.1016/j.jtho.2025.07.117 · 2025
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
10.1001/jama.2008.656 · 2008
Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A
10.1016/j.jtho.2024.12.029 · 2025
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer: results from CHRYSALIS-2
10.1200/jco-24-02835 · 2026
Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2306434 · 2023
Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC
10.1056/nejmoa2503001 · 2025
Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2510308 · 2026
EGFR mutation status on brain metastases from non-small cell lung cancer
10.1016/j.lungcan.2016.04.004 · 2016
Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial
10.1001/jama.2024.10613 · 2024
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development
10.1016/j.ctrv.2024.102824 · 2024
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
10.1016/j.annonc.2025.04.003 · 2025
Unresolved referenced work
2025
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
10.1016/s1470-2045(24)00270-5 · 2024
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
10.1016/j.annonc.2025.01.001 · 2025
No additional external references are available.